tooluniverse-protein-therapeutic-design
Design novel protein therapeutics (binders, enzymes, scaffolds) using AI-guided de novo design. Uses RFdiffusion for backbone generation, ProteinMPNN for sequence design, ESMFold/AlphaFold2 for validation. Use when asked to design protein binders, therapeutic proteins, or engineer protein function.
Best use case
tooluniverse-protein-therapeutic-design is best used when you need a repeatable AI agent workflow instead of a one-off prompt.
Design novel protein therapeutics (binders, enzymes, scaffolds) using AI-guided de novo design. Uses RFdiffusion for backbone generation, ProteinMPNN for sequence design, ESMFold/AlphaFold2 for validation. Use when asked to design protein binders, therapeutic proteins, or engineer protein function.
Teams using tooluniverse-protein-therapeutic-design should expect a more consistent output, faster repeated execution, less prompt rewriting.
When to use this skill
- You want a reusable workflow that can be run more than once with consistent structure.
When not to use this skill
- You only need a quick one-off answer and do not need a reusable workflow.
- You cannot install or maintain the underlying files, dependencies, or repository context.
Installation
Claude Code / Cursor / Codex
Manual Installation
- Download SKILL.md from GitHub
- Place it in
.claude/skills/tooluniverse-protein-therapeutic-design/SKILL.mdinside your project - Restart your AI agent — it will auto-discover the skill
How tooluniverse-protein-therapeutic-design Compares
| Feature / Agent | tooluniverse-protein-therapeutic-design | Standard Approach |
|---|---|---|
| Platform Support | Not specified | Limited / Varies |
| Context Awareness | High | Baseline |
| Installation Complexity | Unknown | N/A |
Frequently Asked Questions
What does this skill do?
Design novel protein therapeutics (binders, enzymes, scaffolds) using AI-guided de novo design. Uses RFdiffusion for backbone generation, ProteinMPNN for sequence design, ESMFold/AlphaFold2 for validation. Use when asked to design protein binders, therapeutic proteins, or engineer protein function.
Where can I find the source code?
You can find the source code on GitHub using the link provided at the top of the page.
SKILL.md Source
# Therapeutic Protein Designer
AI-guided de novo protein design using RFdiffusion backbone generation, ProteinMPNN sequence optimization, and structure validation for therapeutic protein development.
**KEY PRINCIPLES**:
1. **Structure-first design** - Generate backbone geometry before sequence
2. **Target-guided** - Design binders with target structure in mind
3. **Iterative validation** - Predict structure to validate designs
4. **Developability-aware** - Consider aggregation, immunogenicity, expression
5. **Evidence-graded** - Grade designs by confidence metrics
6. **Actionable output** - Provide sequences ready for experimental testing
7. **English-first queries** - Always use English terms in tool calls (protein names, target names), even if the user writes in another language. Only try original-language terms as a fallback. Respond in the user's language
---
## When to Use
Apply when user asks:
- "Design a protein binder for [target]"
- "Create a therapeutic protein against [protein/epitope]"
- "Design a protein scaffold with [property]"
- "Optimize this protein sequence for [function]"
- "Design a de novo enzyme for [reaction]"
- "Generate protein variants for [target binding]"
---
## Critical Workflow Requirements
### 1. Report-First Approach (MANDATORY)
1. **Create the report file FIRST**:
- File name: `[TARGET]_protein_design_report.md`
- Initialize with section headers
- Add placeholder: `[Designing...]`
2. **Progressively update** as designs are generated
3. **Output separate files**:
- `[TARGET]_designed_sequences.fasta` - All designed sequences
- `[TARGET]_top_candidates.csv` - Ranked candidates with metrics
### 2. Design Documentation (MANDATORY)
Every design MUST include:
```markdown
### Design: Binder_001
**Sequence**: MVLSPADKTN...
**Length**: 85 amino acids
**Target**: PD-L1 (UniProt: Q9NZQ7)
**Method**: RFdiffusion → ProteinMPNN → ESMFold validation
**Quality Metrics**:
| Metric | Value | Interpretation |
|--------|-------|----------------|
| pLDDT | 88.5 | High confidence |
| pTM | 0.82 | Good fold |
| ProteinMPNN score | -2.3 | Favorable |
| Predicted binding | Strong | Based on interface pLDDT |
*Source: NVIDIA NIM via `NvidiaNIM_rfdiffusion`, `NvidiaNIM_proteinmpnn`, `NvidiaNIM_esmfold`*
```
---
## Phase 0: Tool Verification
### NVIDIA NIM Tools Required
| Tool | Purpose | API Key Required |
|------|---------|------------------|
| `NvidiaNIM_rfdiffusion` | Backbone generation | Yes |
| `NvidiaNIM_proteinmpnn` | Sequence design | Yes |
| `NvidiaNIM_esmfold` | Fast structure validation | Yes |
| `NvidiaNIM_alphafold2` | High-accuracy validation | Yes |
| `NvidiaNIM_esm2_650m` | Sequence embeddings | Yes |
### Parameter Verification
| Tool | WRONG Parameter | CORRECT Parameter |
|------|-----------------|-------------------|
| `NvidiaNIM_rfdiffusion` | `num_steps` | `diffusion_steps` |
| `NvidiaNIM_proteinmpnn` | `pdb` | `pdb_string` |
| `NvidiaNIM_esmfold` | `seq` | `sequence` |
---
## Workflow Overview
```
Phase 1: Target Characterization
├── Get target structure (PDB, EMDB cryo-EM, or AlphaFold)
├── Identify binding epitope
├── Analyze existing binders
├── Check EMDB for membrane protein structures (NEW)
└── OUTPUT: Target profile
↓
Phase 2: Backbone Generation (RFdiffusion)
├── Define design constraints
├── Generate multiple backbones
├── Filter by geometry quality
└── OUTPUT: Candidate backbones
↓
Phase 3: Sequence Design (ProteinMPNN)
├── Design sequences for each backbone
├── Sample multiple sequences per backbone
├── Score by ProteinMPNN likelihood
└── OUTPUT: Designed sequences
↓
Phase 4: Structure Validation
├── Predict structure (ESMFold/AlphaFold2)
├── Compare to designed backbone
├── Assess fold quality (pLDDT, pTM)
└── OUTPUT: Validated designs
↓
Phase 5: Developability Assessment
├── Aggregation propensity
├── Expression likelihood
├── Immunogenicity prediction
└── OUTPUT: Developability scores
↓
Phase 6: Report Synthesis
├── Ranked candidate list
├── Experimental recommendations
├── Next steps
└── OUTPUT: Final report
```
---
## Phase 1: Target Characterization
### 1.1 Get Target Structure
```python
def get_target_structure(tu, target_id):
"""Get target structure from PDB, EMDB, or predict."""
# Try PDB first (X-ray/NMR)
pdb_results = tu.tools.PDB_search_by_uniprot(uniprot_id=target_id)
if pdb_results:
# Get highest resolution structure
best_pdb = sorted(pdb_results, key=lambda x: x['resolution'])[0]
structure = tu.tools.PDB_get_structure(pdb_id=best_pdb['pdb_id'])
return {'source': 'PDB', 'pdb_id': best_pdb['pdb_id'],
'resolution': best_pdb['resolution'], 'structure': structure}
# Try EMDB for cryo-EM structures (valuable for membrane proteins)
protein_info = tu.tools.UniProt_get_protein_by_accession(accession=target_id)
emdb_results = tu.tools.emdb_search(
query=protein_info['proteinDescription']['recommendedName']['fullName']['value']
)
if emdb_results and len(emdb_results) > 0:
# Get highest resolution cryo-EM entry
best_emdb = sorted(emdb_results, key=lambda x: x.get('resolution', 99))[0]
# Get associated PDB model if available
emdb_details = tu.tools.emdb_get_entry(entry_id=best_emdb['emdb_id'])
if emdb_details.get('pdb_ids'):
structure = tu.tools.PDB_get_structure(pdb_id=emdb_details['pdb_ids'][0])
return {'source': 'EMDB cryo-EM', 'emdb_id': best_emdb['emdb_id'],
'pdb_id': emdb_details['pdb_ids'][0],
'resolution': best_emdb.get('resolution'), 'structure': structure}
# Fallback to AlphaFold prediction
sequence = tu.tools.UniProt_get_protein_sequence(accession=target_id)
structure = tu.tools.NvidiaNIM_alphafold2(
sequence=sequence['sequence'],
algorithm="mmseqs2"
)
return {'source': 'AlphaFold2 (predicted)', 'structure': structure}
```
### 1.1b EMDB for Membrane Proteins (NEW)
**When to prioritize EMDB**: Membrane proteins, large complexes, and targets where conformational states matter.
```python
def get_cryoem_structures(tu, target_name):
"""Get cryo-EM structures for membrane proteins/complexes."""
# Search EMDB
emdb_results = tu.tools.emdb_search(
query=f"{target_name} membrane OR receptor"
)
structures = []
for entry in emdb_results[:5]:
details = tu.tools.emdb_get_entry(entry_id=entry['emdb_id'])
structures.append({
'emdb_id': entry['emdb_id'],
'resolution': entry.get('resolution', 'N/A'),
'title': entry.get('title', 'N/A'),
'conformational_state': details.get('state', 'Unknown'),
'pdb_models': details.get('pdb_ids', [])
})
return structures
```
**Output for Report**:
```markdown
### 1.1b Cryo-EM Structures (EMDB)
| EMDB ID | Resolution | PDB Model | Conformation |
|---------|------------|-----------|--------------|
| EMD-12345 | 2.8 Å | 7ABC | Active state |
| EMD-23456 | 3.1 Å | 8DEF | Inactive state |
**Note**: Cryo-EM structures capture physiologically relevant conformations for membrane protein targets.
*Source: EMDB*
```
### 1.2 Identify Binding Epitope
```python
def identify_epitope(tu, target_structure, epitope_residues=None):
"""Identify or validate binding epitope."""
if epitope_residues:
# User-specified epitope
return {'residues': epitope_residues, 'source': 'user-defined'}
# Find surface-exposed regions
# Use structural analysis to identify potential epitopes
return analyze_surface(target_structure)
```
### 1.3 Output for Report
```markdown
## 1. Target Characterization
### 1.1 Target Information
| Property | Value |
|----------|-------|
| **Target** | PD-L1 (Programmed death-ligand 1) |
| **UniProt** | Q9NZQ7 |
| **Structure source** | PDB: 4ZQK (2.0 Å resolution) |
| **Binding epitope** | IgV domain, residues 19-127 |
| **Known binders** | Atezolizumab, durvalumab, avelumab |
### 1.2 Epitope Analysis
| Residue Range | Type | Surface Area | Druggability |
|---------------|------|--------------|--------------|
| 54-68 | Loop | 850 Ų | High |
| 115-125 | Beta strand | 420 Ų | Medium |
| 19-30 | N-terminus | 380 Ų | Medium |
**Selected Epitope**: Residues 54-68 (PD-1 binding interface)
*Source: PDB 4ZQK, surface analysis*
```
---
## Phase 2: Backbone Generation
### 2.1 RFdiffusion Design
```python
def generate_backbones(tu, design_params):
"""Generate de novo backbones using RFdiffusion."""
backbones = tu.tools.NvidiaNIM_rfdiffusion(
diffusion_steps=design_params.get('steps', 50),
# Additional parameters depending on design type
)
return backbones
```
### 2.2 Design Modes
| Mode | Use Case | Key Parameters |
|------|----------|----------------|
| **Unconditional** | De novo scaffold | `diffusion_steps` only |
| **Binder design** | Target-guided binder | `target_structure`, `hotspot_residues` |
| **Motif scaffolding** | Functional motif embedding | `motif_sequence`, `motif_structure` |
### 2.3 Output for Report
```markdown
## 2. Backbone Generation
### 2.1 Design Parameters
| Parameter | Value |
|-----------|-------|
| **Method** | RFdiffusion via NVIDIA NIM |
| **Design mode** | Unconditional scaffold generation |
| **Diffusion steps** | 50 |
| **Number generated** | 10 backbones |
### 2.2 Generated Backbones
| Backbone | Length | Topology | Quality |
|----------|--------|----------|---------|
| BB_001 | 85 aa | 3-helix bundle | Good |
| BB_002 | 92 aa | Beta sandwich | Good |
| BB_003 | 78 aa | Alpha-beta | Good |
| BB_004 | 88 aa | All-alpha | Moderate |
| BB_005 | 95 aa | Mixed | Good |
**Selected for sequence design**: BB_001, BB_002, BB_003, BB_005 (top 4)
*Source: NVIDIA NIM via `NvidiaNIM_rfdiffusion`*
```
---
## Phase 3: Sequence Design
### 3.1 ProteinMPNN Design
```python
def design_sequences(tu, backbone_pdb, num_sequences=8):
"""Design sequences for backbone using ProteinMPNN."""
sequences = tu.tools.NvidiaNIM_proteinmpnn(
pdb_string=backbone_pdb,
num_sequences=num_sequences,
temperature=0.1 # Lower = more conservative
)
return sequences
```
### 3.2 Sampling Parameters
| Parameter | Conservative | Moderate | Diverse |
|-----------|--------------|----------|---------|
| Temperature | 0.1 | 0.2 | 0.5 |
| Sequences per backbone | 4 | 8 | 16 |
| Use case | Validated scaffold | Exploration | Diversity |
### 3.3 Output for Report
```markdown
## 3. Sequence Design
### 3.1 Design Parameters
| Parameter | Value |
|-----------|-------|
| **Method** | ProteinMPNN via NVIDIA NIM |
| **Temperature** | 0.1 (conservative) |
| **Sequences per backbone** | 8 |
| **Total sequences** | 32 |
### 3.2 Designed Sequences (Top 10 by Score)
| Rank | Backbone | Sequence ID | Length | MPNN Score | Predicted pI |
|------|----------|-------------|--------|------------|--------------|
| 1 | BB_001 | Seq_001_A | 85 | -1.89 | 6.2 |
| 2 | BB_002 | Seq_002_C | 92 | -1.95 | 5.8 |
| 3 | BB_001 | Seq_001_B | 85 | -2.01 | 7.1 |
| 4 | BB_003 | Seq_003_A | 78 | -2.08 | 6.5 |
| 5 | BB_005 | Seq_005_B | 95 | -2.12 | 5.4 |
### 3.3 Top Sequence: Seq_001_A
```
>Seq_001_A (85 aa, MPNN score: -1.89)
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSH
GSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKL
```
*Source: NVIDIA NIM via `NvidiaNIM_proteinmpnn`*
```
---
## Phase 4: Structure Validation
### 4.1 ESMFold Validation
```python
def validate_structure(tu, sequence):
"""Validate designed sequence by structure prediction."""
# Fast validation with ESMFold
predicted = tu.tools.NvidiaNIM_esmfold(sequence=sequence)
# Extract quality metrics
plddt = extract_plddt(predicted)
ptm = extract_ptm(predicted)
return {
'structure': predicted,
'mean_plddt': np.mean(plddt),
'ptm': ptm,
'passes': np.mean(plddt) > 70 and ptm > 0.7
}
```
### 4.2 Validation Criteria
| Metric | Threshold | Interpretation |
|--------|-----------|----------------|
| Mean pLDDT | >70 | Confident fold |
| pTM | >0.7 | Good global topology |
| RMSD to backbone | <2 Å | Design recapitulated |
### 4.3 Output for Report
```markdown
## 4. Structure Validation
### 4.1 Validation Results
| Sequence | pLDDT | pTM | RMSD to Design | Status |
|----------|-------|-----|----------------|--------|
| Seq_001_A | 88.5 | 0.85 | 1.2 Å | ✓ PASS |
| Seq_002_C | 82.3 | 0.79 | 1.5 Å | ✓ PASS |
| Seq_001_B | 85.1 | 0.82 | 1.3 Å | ✓ PASS |
| Seq_003_A | 79.8 | 0.76 | 1.8 Å | ✓ PASS |
| Seq_005_B | 68.2 | 0.65 | 2.8 Å | ✗ FAIL |
### 4.2 Top Validated Design: Seq_001_A
| Region | Residues | pLDDT | Interpretation |
|--------|----------|-------|----------------|
| Helix 1 | 1-28 | 92.3 | Very high confidence |
| Loop 1 | 29-35 | 78.4 | Moderate confidence |
| Helix 2 | 36-58 | 91.8 | Very high confidence |
| Loop 2 | 59-65 | 75.2 | Moderate confidence |
| Helix 3 | 66-85 | 90.1 | Very high confidence |
**Overall**: Well-folded 3-helix bundle with high confidence core
*Source: NVIDIA NIM via `NvidiaNIM_esmfold`*
```
---
## Phase 5: Developability Assessment
### 5.1 Aggregation Propensity
```python
def assess_aggregation(sequence):
"""Assess aggregation propensity."""
# Calculate hydrophobic patches
# Calculate isoelectric point
# Identify aggregation-prone motifs
return {
'aggregation_score': score,
'hydrophobic_patches': patches,
'risk_level': 'Low' if score < 0.5 else 'Medium' if score < 0.7 else 'High'
}
```
### 5.2 Developability Metrics
| Metric | Favorable | Marginal | Unfavorable |
|--------|-----------|----------|-------------|
| Aggregation score | <0.5 | 0.5-0.7 | >0.7 |
| Isoelectric point | 5-9 | 4-5 or 9-10 | <4 or >10 |
| Hydrophobic patches | <3 | 3-5 | >5 |
| Cysteine count | 0 or even | Odd | Multiple unpaired |
### 5.3 Output for Report
```markdown
## 5. Developability Assessment
### 5.1 Developability Scores
| Design | Aggregation | pI | Cysteines | Expression | Overall |
|--------|-------------|-----|-----------|------------|---------|
| Seq_001_A | 0.32 (Low) | 6.2 | 0 | High | ★★★ |
| Seq_002_C | 0.45 (Low) | 5.8 | 2 (paired) | Medium | ★★☆ |
| Seq_001_B | 0.38 (Low) | 7.1 | 0 | High | ★★★ |
| Seq_003_A | 0.58 (Med) | 6.5 | 0 | Medium | ★★☆ |
### 5.2 Recommendations
**Best candidate for expression**: Seq_001_A
- Low aggregation propensity
- Neutral pI (easy purification)
- No cysteines (no misfolding risk)
- Predicted high E. coli expression
*Source: Sequence analysis*
```
---
## Report Template
```markdown
# Therapeutic Protein Design Report: [TARGET]
**Generated**: [Date] | **Query**: [Original query] | **Status**: In Progress
---
## Executive Summary
[Designing...]
---
## 1. Target Characterization
### 1.1 Target Information
[Designing...]
### 1.2 Binding Epitope
[Designing...]
---
## 2. Backbone Generation
### 2.1 Design Parameters
[Designing...]
### 2.2 Generated Backbones
[Designing...]
---
## 3. Sequence Design
### 3.1 ProteinMPNN Results
[Designing...]
### 3.2 Top Sequences
[Designing...]
---
## 4. Structure Validation
### 4.1 ESMFold Validation
[Designing...]
### 4.2 Quality Metrics
[Designing...]
---
## 5. Developability Assessment
### 5.1 Scores
[Designing...]
### 5.2 Recommendations
[Designing...]
---
## 6. Final Candidates
### 6.1 Ranked List
[Designing...]
### 6.2 Sequences for Testing
[Designing...]
---
## 7. Experimental Recommendations
[Designing...]
---
## 8. Data Sources
[Will be populated...]
```
---
## Evidence Grading
| Tier | Symbol | Criteria |
|------|--------|----------|
| **T1** | ★★★ | pLDDT >85, pTM >0.8, low aggregation, neutral pI |
| **T2** | ★★☆ | pLDDT >75, pTM >0.7, acceptable developability |
| **T3** | ★☆☆ | pLDDT >70, pTM >0.65, developability concerns |
| **T4** | ☆☆☆ | Failed validation or major developability issues |
---
## Completeness Checklist
### Phase 1: Target
- [ ] Target structure obtained (PDB or predicted)
- [ ] Binding epitope identified
- [ ] Existing binders noted
### Phase 2: Backbones
- [ ] ≥5 backbones generated
- [ ] Top 3-5 selected for sequence design
- [ ] Selection criteria documented
### Phase 3: Sequences
- [ ] ≥8 sequences per backbone designed
- [ ] MPNN scores reported
- [ ] Top 10 sequences listed
### Phase 4: Validation
- [ ] All sequences validated by ESMFold
- [ ] pLDDT and pTM reported
- [ ] Pass/fail criteria applied
- [ ] ≥3 passing designs
### Phase 5: Developability
- [ ] Aggregation assessed
- [ ] pI calculated
- [ ] Expression prediction
- [ ] Final ranking
### Phase 6: Deliverables
- [ ] Ranked candidate list
- [ ] FASTA file with sequences
- [ ] Experimental recommendations
---
## Fallback Chains
| Primary Tool | Fallback 1 | Fallback 2 |
|--------------|------------|------------|
| `NvidiaNIM_rfdiffusion` | Manual backbone design | Scaffold from PDB |
| `NvidiaNIM_proteinmpnn` | Rosetta ProteinMPNN | Manual sequence design |
| `NvidiaNIM_esmfold` | `NvidiaNIM_alphafold2` | AlphaFold DB |
| PDB structure | `NvidiaNIM_alphafold2` | AlphaFold DB |
---
## Tool Reference
See [TOOLS_REFERENCE.md](TOOLS_REFERENCE.md) for complete tool documentation.Related Skills
tooluniverse-variant-interpretation
Systematic clinical variant interpretation from raw variant calls to ACMG-classified recommendations with structural impact analysis. Aggregates evidence from ClinVar, gnomAD, CIViC, UniProt, and PDB across ACMG criteria. Produces pathogenicity scores (0-100), clinical recommendations, and treatment implications. Use when interpreting genetic variants, classifying variants of uncertain significance (VUS), performing ACMG variant classification, or translating variant calls to clinical actionability.
tooluniverse-variant-analysis
Production-ready VCF processing, variant annotation, mutation analysis, and structural variant (SV/CNV) interpretation for bioinformatics questions. Parses VCF files (streaming, large files), classifies mutation types (missense, nonsense, synonymous, frameshift, splice, intronic, intergenic) and structural variants (deletions, duplications, inversions, translocations), applies VAF/depth/quality/consequence filters, annotates with ClinVar/dbSNP/gnomAD/CADD via ToolUniverse, interprets SV/CNV clinical significance using ClinGen dosage sensitivity scores, computes variant statistics, and generates reports. Solves questions like "What fraction of variants with VAF < 0.3 are missense?", "How many non-reference variants remain after filtering intronic/intergenic?", "What is the pathogenicity of this deletion affecting BRCA1?", or "Which dosage-sensitive genes overlap this CNV?". Use when processing VCF files, annotating variants, filtering by VAF/depth/consequence, classifying mutations, interpreting structural variants, assessing CNV pathogenicity, comparing cohorts, or answering variant analysis questions.
tooluniverse-target-research
Gather comprehensive biological target intelligence from 9 parallel research paths covering protein info, structure, interactions, pathways, expression, variants, drug interactions, and literature. Features collision-aware searches, evidence grading (T1-T4), explicit Open Targets coverage, and mandatory completeness auditing. Use when users ask about drug targets, proteins, genes, or need target validation, druggability assessment, or comprehensive target profiling.
tooluniverse-systems-biology
Comprehensive systems biology and pathway analysis using multiple pathway databases (Reactome, KEGG, WikiPathways, Pathway Commons, BioModels). Performs pathway enrichment, protein-pathway mapping, keyword searches, and systems-level analysis. Use when analyzing gene sets, exploring biological pathways, or investigating systems-level biology.
tooluniverse-structural-variant-analysis
Comprehensive structural variant (SV) analysis skill for clinical genomics. Classifies SVs (deletions, duplications, inversions, translocations), assesses pathogenicity using ACMG-adapted criteria, evaluates gene disruption and dosage sensitivity, and provides clinical interpretation with evidence grading. Use when analyzing CNVs, large deletions/duplications, chromosomal rearrangements, or any structural variants requiring clinical interpretation.
tooluniverse-statistical-modeling
Perform statistical modeling and regression analysis on biomedical datasets. Supports linear regression, logistic regression (binary/ordinal/multinomial), mixed-effects models, Cox proportional hazards survival analysis, Kaplan-Meier estimation, and comprehensive model diagnostics. Extracts odds ratios, hazard ratios, confidence intervals, p-values, and effect sizes. Designed to solve BixBench statistical reasoning questions involving clinical/experimental data. Use when asked to fit regression models, compute odds ratios, perform survival analysis, run statistical tests, or interpret model coefficients from provided data.
tooluniverse-spatial-transcriptomics
Analyze spatial transcriptomics data to map gene expression in tissue architecture. Supports 10x Visium, MERFISH, seqFISH, Slide-seq, and imaging-based platforms. Performs spatial clustering, domain identification, cell-cell proximity analysis, spatial gene expression patterns, tissue architecture mapping, and integration with single-cell data. Use when analyzing spatial transcriptomics datasets, studying tissue organization, identifying spatial expression patterns, mapping cell-cell interactions in tissue context, characterizing tumor microenvironment spatial structure, or integrating spatial and single-cell RNA-seq data for comprehensive tissue analysis.
tooluniverse-spatial-omics-analysis
Computational analysis framework for spatial multi-omics data integration. Given spatially variable genes (SVGs), spatial domain annotations, tissue type, and disease context from spatial transcriptomics/proteomics experiments (10x Visium, MERFISH, DBiTplus, SLIDE-seq, etc.), performs comprehensive biological interpretation including pathway enrichment, cell-cell interaction inference, druggable target identification, immune microenvironment characterization, and multi-modal integration. Produces a detailed markdown report with Spatial Omics Integration Score (0-100), domain-by-domain characterization, and validation recommendations. Uses 70+ ToolUniverse tools across 9 analysis phases. Use when users ask about spatial transcriptomics analysis, spatial omics interpretation, tissue heterogeneity, spatial gene expression patterns, tumor microenvironment mapping, tissue zonation, or cell-cell communication from spatial data.
tooluniverse-single-cell
Production-ready single-cell and expression matrix analysis using scanpy, anndata, and scipy. Performs scRNA-seq QC, normalization, PCA, UMAP, Leiden/Louvain clustering, differential expression (Wilcoxon, t-test, DESeq2), cell type annotation, per-cell-type statistical analysis, gene-expression correlation, batch correction (Harmony), trajectory inference, and cell-cell communication analysis. NEW: Analyzes ligand-receptor interactions between cell types using OmniPath (CellPhoneDB, CellChatDB), scores communication strength, identifies signaling cascades, and handles multi-subunit receptor complexes. Integrates with ToolUniverse gene annotation tools (HPA, Ensembl, MyGene, UniProt) and enrichment tools (gseapy, PANTHER, STRING). Supports h5ad, 10X, CSV/TSV count matrices, and pre-annotated datasets. Use when analyzing single-cell RNA-seq data, studying cell-cell interactions, performing cell type differential expression, computing gene-expression correlations by cell type, analyzing tumor-immune communication, or answering questions about scRNA-seq datasets.
tooluniverse-sequence-retrieval
Retrieves biological sequences (DNA, RNA, protein) from NCBI and ENA with gene disambiguation, accession type handling, and comprehensive sequence profiles. Creates detailed reports with sequence metadata, cross-database references, and download options. Use when users need nucleotide sequences, protein sequences, genome data, or mention GenBank, RefSeq, EMBL accessions.
tooluniverse-rnaseq-deseq2
Production-ready RNA-seq differential expression analysis using PyDESeq2. Performs DESeq2 normalization, dispersion estimation, Wald testing, LFC shrinkage, and result filtering. Handles multi-factor designs, multiple contrasts, batch effects, and integrates with gene enrichment (gseapy) and ToolUniverse annotation tools (UniProt, Ensembl, OpenTargets). Supports CSV/TSV/H5AD input formats and any organism. Use when analyzing RNA-seq count matrices, identifying DEGs, performing differential expression with statistical rigor, or answering questions about gene expression changes.
tooluniverse-rare-disease-diagnosis
Provide differential diagnosis for patients with suspected rare diseases based on phenotype and genetic data. Matches symptoms to HPO terms, identifies candidate diseases from Orphanet/OMIM, prioritizes genes for testing, interprets variants of uncertain significance. Use when clinician asks about rare disease diagnosis, unexplained phenotypes, or genetic testing interpretation.